QURE
Uniqure NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.14B
P/E Ratio
—
EPS
$-3.46
Beta
0.75
52W High
$71.50
52W Low
$8.73
50-Day MA
$17.06
200-Day MA
$25.39
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
27.93
PEG Ratio
0.00
About Uniqure NV
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Fundamentals
| Revenue (TTM) | $16.10M |
| Gross Profit (TTM) | $-120.01M |
| EBITDA | $-164.34M |
| Operating Margin | -901.00% |
| Return on Equity | -207.10% |
| Return on Assets | -16.20% |
| Revenue/Share (TTM) | $0.28 |
| Book Value | $3.19 |
| Price-to-Book | 5.67 |
| Price-to-Sales (TTM) | 70.68 |
| EV/Revenue | 35.36 |
| EV/EBITDA | 1.40 |
| Quarterly Earnings Growth (YoY) | -18.20% |
| Quarterly Revenue Growth (YoY) | 6.60% |
| Shares Outstanding | $63.03M |
| Float | $49.29M |
| % Insiders | 5.61% |
| % Institutions | 99.78% |
Historical Volatility
HV 10-Day
56.84%
HV 20-Day
80.41%
HV 30-Day
83.51%
HV 60-Day
165.58%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($38.43 target)
1
Strong Buy8
Buy4
HoldData last updated: 4/29/2026